BRMS1 transcriptional repressor and anoikis regulatorGenealiases: []
Q-omics provides the consensus-scored BRMS1 profile across patient tissues and cancer cell-line models. BRMS1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, BRMS1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, BRMS1 RNA expression shows 19,474 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, HNSC, and THYM as cancer lineages where BRMS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BRMS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BRMS1 survival associations across molecular data types. BRMS1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BRMS1 RNA expression–survival associations across cancer types. High BRMS1 expression shows unfavorable associations in KICH, ACC, LIHC and KIRC, but favorable associations in STAD and SCLC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for BRMS1 RNA expression.
This table summarizes BRMS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BRMS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BRMS1 shows higher tumor expression in HNSC, BLCA, STAD, LIHC, KIRC and LUSC. The HNSC box plot shows higher BRMS1 RNA expression in tumor versus normal tissue (log2 FC = +1.403, t-test p < 0.001).
This table shows molecular features associated with BRMS1 in patient tissues and cancer cell lines. In patient samples, BRMS1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, BRMS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
